PROTOMED LIMITED

1. Financial Health Score: F

Explanation: Protomed Limited has been assigned a grade of 'F' because the patient is, in corporate terms, deceased. The company is currently in "Liquidation," which is the absolute lowest point on the corporate health spectrum. This is the financial equivalent of cardiac arrest—operations have ceased, and the entity is being formally wound down. There is no longer a going concern to rehabilitate; the focus has shifted entirely to the disposal of remaining assets and the settlement of debts.

2. Key Vital Signs

• Corporate Pulse (Company Status): Liquidation. The patient has no pulse. A liquidation status means the company has been formally placed into a process to close its doors, sell off assets, and distribute whatever proceeds remain to creditors.
• Medical Records (Filing Compliance): Critically Neglected. The company’s accounts are massively overdue (last filed for January 2017, due by March 2019) and the confirmation statement is also overdue. This is akin to a patient refusing to attend follow-up appointments or take vital medication. In a liquidation scenario, this is a common symptom; the internal machinery of the business has ground to a halt, and administrative compliance is abandoned.
• Bloodline (Ownership & Control): The People with Significant Control (PSC) registers show that Quantum Pharma Group Limited and Quantum Pharmaceutical Limited hold over 75% of the shares and voting rights. These parent entities act as the "surgeons" deciding the patient's fate, and they have clearly opted to terminate the subsidiary rather than inject further capital.
• Organ Function (Nature of Business): Operating in "Other human health activities" (SIC 86900), there is a bitter irony here. While the company's purpose was to support human health, it was entirely unable to maintain its own corporate wellbeing.

3. Diagnosis

Terminal Corporate Distress. The financial data reveals a business that has suffered a complete systemic failure. The transition into Liquidation indicates that Protomed Limited was experiencing severe, unresolvable symptoms of financial distress—likely chronic insolvency or an inability to meet its financial obligations as they fell due.

The parent companies (Quantum Pharma Group and Quantum Pharmaceutical Limited) have essentially issued a "Do Not Resuscitate" order. When majority owners allow a subsidiary to go into liquidation rather than providing financial life support, it typically means the business was bleeding cash, structurally unsound, or no longer served a strategic purpose within the wider corporate body. The severely overdue filings confirm that the internal organs of the company (finance and administration) stopped functioning long before the formal end was declared.

4. Recommendations

Because the patient is in Liquidation, standard financial wellness recommendations—such as improving cash flow or restructuring debt—no longer apply. Instead, the focus shifts to managing the aftermath and preventing contagion:

• For the Parent Company (Quantum Pharma): Ensure a clean and swift liquidation process. Lingering, unresolved liquidations can cause administrative infections within the wider corporate group. Ensure all preferential and unsecured creditors are dealt with fairly to avoid director disqualification claims or legal action that could impact the parent company's health.
• For the Directors: Cooperate fully with the appointed liquidator. Just as a doctor needs an accurate medical history before closing a file, the liquidator needs complete transparency regarding the company's final days. Failure to provide records could lead to investigations by the Insolvency Service and potential disqualification.
• For Creditors: File your claims with the liquidator immediately. The prognosis for recovering outstanding debts is poor, but establishing your place in the creditor hierarchy is the only way to receive any remaining distributions from the company's final "estate."